[Business Wire] - BioCryst Pharmaceuticals, Inc. today announced that it received a preliminary comment letter from the U.S. Food & Drug Administration that outlines a pathway by which BioCryst could file a New Drug Application seeking regulatory approval of intravenous peramivir.
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment